Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Changes in Quality-of-Life Parameters in Patients Receiving Therapeutic Interventions for Cancer-Associated Anemia: A Systematic Review

Snigdha Marivada, Sandhya R. Panch, Kamyab Pirouz, Chhaya Kamwal, Alexandra Dreyzin, Alicia Livinski, David F. Stroncek, Xiaobai Li, Barbara Bryant

Blood (2021) 138 (Supplement 1): 2142.

https://doi.org/10.1182/blood-2021-152843

Published: 2021

Journal Articles

EZH2 Inhibitors Are Broadly Efficacious in Multiple Myeloma As Single Agent and in Combination with Standard of Care Therapeutics

Shilpi Arora, PhD, Kaylyn Williamson, BS, Shruti Apte, BS, Srividya Balachander, PhD, Jennifer Busby, PhD, Charlie Hatton, PhD, Barbara Bryant, PhD, Patrick Trojer, PhD

Blood (2016) 128 (22): 5672.

https://doi.org/10.1182/blood.V128.22.5672.5672

Published: 2016

Journal Articles

Development of BET Protein Bromodomain Inhibition for the Treatment of Hematologic Malignancies

Robert Sims, PhD, Emmanuel Normant, PharmD, PhD, Peter Sandy, PhD, Jennifer Mertz, PhD, Barbara Bryant, PhD, Michael O'Meara, MS, Marie Green, PhD, Michael Cooper, MD, Jim Audia, PhD

Blood (2012) 120 (21): 1331.

https://doi.org/10.1182/blood.V120.21.1331.1331

Published: 2012

Journal Articles

The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition

Wee J. Chng, Esteban Braggio, George Mulligan, Barbara Bryant, Ellen Remstein, Riccardo Valdez, Ahmet Dogan, Rafael Fonseca

Blood (2008) 111 (3): 1603–1609.

https://doi.org/10.1182/blood-2007-06-097774

Published: 2008

Includes: Supplemental data

Journal Articles

Survival of genetic subtypes of relapsed myeloma may be modulated by secondary events

Wee J. Chng, George Mulligan, Barbara Bryant, Leif Bergsagel

Blood (2007) 109 (8): 3610–3611.

https://doi.org/10.1182/blood-2006-09-048769

Published: 2007

Journal Articles

Survival of Genetic Subtypes of Relapsed Myeloma May Be Modulated by Secondary Events.

Wee-Joo Chng, MD, George Mulligan, PhD, Barbara Bryant, PhD, Peter Leif Bergsagel, MD

Blood (2006) 108 (11): 132.

https://doi.org/10.1182/blood.V108.11.132.132

Published: 2006

NARROW

Changes in Quality-of-Life Parameters in Patients Receiving Therapeutic Interventions for Cancer-Associated Anemia: A Systematic Review

EZH2 Inhibitors Are Broadly Efficacious in Multiple Myeloma As Single Agent and in Combination with Standard of Care Therapeutics

Development of BET Protein Bromodomain Inhibition for the Treatment of Hematologic Malignancies

The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition

Survival of genetic subtypes of relapsed myeloma may be modulated by secondary events

Survival of Genetic Subtypes of Relapsed Myeloma May Be Modulated by Secondary Events.

Email alerts

ASH Publications

American Society of Hematology

Changes in Quality-of-Life Parameters in Patients Receiving Therapeutic Interventions for Cancer-Associated Anemia: A Systematic Review

EZH2 Inhibitors Are Broadly Efficacious in Multiple Myeloma As Single Agent and in Combination with Standard of Care Therapeutics

Development of BET Protein Bromodomain Inhibition for the Treatment of Hematologic Malignancies

The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition

Survival of genetic subtypes of relapsed myeloma may be modulated by secondary events

Survival of Genetic Subtypes of Relapsed Myeloma May Be Modulated by Secondary Events.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only